Addressing patient heterogeneity in disease predictive model development
From MaRDI portal
Publication:6079586
DOI10.1111/BIOM.13514zbMath1520.62207arXiv2101.02439MaRDI QIDQ6079586
Ziding Feng, Jing Ning, Weining Shen, Jianhua Hu, Xu Gao
Publication date: 30 October 2023
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://arxiv.org/abs/2101.02439
heterogeneitymixture modelprostate cancergeneralized linear modelsubgroup analysisexpectation maximization
Cites Work
- Unnamed Item
- Hypothesis test for normal mixture models: the EM approach
- Penalized likelihood for logistic-normal mixture models with unequal variances
- Testing homogeneity in a multivariate mixture model
- Analysis of randomized comparative clinical trial data for personalized treatment selections
- Evaluating Markers for Selecting a Patient's Treatment
- Inference on the Order of a Normal Mixture
- Homogeneity testing under finite location‐scale mixtures
- Testing the Order of a Finite Mixture
- Effectively Selecting a Target Population for a Future Comparative Study
- Inference for Subgroup Analysis With a Structured Logistic-Normal Mixture Model
- Patterns of treatment effects in subsets of patients in clinical trials
This page was built for publication: Addressing patient heterogeneity in disease predictive model development